Home
UCB And Biogen Announced Positive Topline Results Phase 3 Study of Dapirolizumab Pegol for Systemic Lupus Erythematosus

UCB And Biogen Announced Positive Topline Results Phase 3 Study of Dapirolizumab Pegol for Systemic Lupus Erythematosus

Today’s Highlights September 24, 2024

UCB and Biogen Positive Results

UCB (Euronext Brussels: UCB) and Biogen Inc. (BIIB) announced positive . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.
Today’s Highlights
,
September 24, 2024

Other Articles